Next Generation Transcriptomics-based Precision Oncology
During this webinar, Computational Biologist Dr. Eytan Ruppin will present on “SELECT,” a computational approach that aims to identify clinically relevant synthetic lethal interactions, thereby harnessing them to predict patient response to cancer therapy from the bulk tumor transcriptome.
Tested on a broad collection of targeted and immunotherapy clinical trials, SELECT is predictive of patients’ response in 80% of those and in the recent multi-arm WINTHER clinical trial.
The session will also cover:
- “MadHitter” and “PERCEPTION,” two new computational approaches for guiding precision cancer therapy based on single cell tumor transcriptomics.
- future challenges that need to be addressed to further advance transcriptomics-based precision oncology, including the development of a new precision oncology expression-based approach starting from histopathological images.
The Data Science Seminar Series presents talks from innovators in the cancer research and informatics communities both within and outside of NCI.
Dr. Ruppin is the chief and senior investigator of NCI’s Cancer Data Science Laboratory. He’s a trained computational biologist whose research is focused on developing and harnessing data science approaches for the integration of multi-omics data to better understand the pathogenesis of cancer, its evolution, and treatment.